Octagon Capital Advisors’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,868,000
| Closed | -$35.7M | – | 61 |
|
|
2023
Q4 | $35.7M | Sell |
1,868,000
-100,000
| -5% | -$1.91M | 5.71% | 5 |
|
|
2023
Q3 | $35.3M | Hold |
1,968,000
| – | – | 5.43% | 5 |
|
|
2023
Q2 | $40M | Sell |
1,968,000
-204,000
| -9% | -$4.14M | 5.56% | 4 |
|
|
2023
Q1 | $39.6M | Sell |
2,172,000
-310,700
| -13% | -$5.67M | 5.7% | 5 |
|
|
2022
Q4 | $51.3M | Sell |
2,482,700
-185,616
| -7% | -$3.84M | 7.99% | 4 |
|
|
2022
Q3 | $69.8M | Sell |
2,668,316
-1,658
| -0.1% | -$43.4K | 12.05% | 2 |
|
|
2022
Q2 | $67.7M | Buy |
2,669,974
+180,000
| +7% | +$4.56M | 18.06% | 2 |
|
|
2022
Q1 | $78.6M | Buy |
2,489,974
+394,743
| +19% | +$12.5M | 16.99% | 2 |
|
|
2021
Q4 | $84.8M | Buy |
2,095,231
+1,125,067
| +116% | +$45.5M | 16.5% | 2 |
|
|
2021
Q3 | $33.8M | Buy |
970,164
+210,000
| +28% | +$7.32M | 8.33% | 4 |
|
|
2021
Q2 | $20.9M | Buy |
760,164
+360,164
| +90% | +$9.89M | 4.32% | 5 |
|
|
2021
Q1 | $11.2M | Buy |
400,000
+100,000
| +33% | +$2.81M | 4.23% | 10 |
|
|
2020
Q4 | $7.79M | Buy |
+300,000
| New | +$7.79M | 2.7% | 15 |
|